Navigation Links
Cardiovascular Researchers Use MEDIHONEY(TM) on Sternal Infections Following Open-Heart Procedures

Full Clinical Study Initiated Following Success with 8 Patients

PRINCETON, N.J., May 13 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, today announced that a group of cardiovascular and thoracic surgeons from the University of Wurzburg, Germany, have used MEDIHONEY(TM) dressings to successfully treat 8 patients with deep sternal wound infections (DSWI), a condition that sometimes arises after open-heart surgeries. The dressings were used in combination with V.A.C.(R) Therapy (KCI, San Antonio, Texas), the largest and fastest growing technology in advanced wound care. Based on the successful results of this observational study, the researchers have initiated a prospective, randomized, controlled study on the influence of MEDIHONEY on the treatment of DSWI.

Derma Sciences CEO Ed Quilty stated, "The results from this initial 8-patient study are very encouraging. DSWI adds significant additional hospitalization costs to median sternotomy and coronary artery bypass grafting (CABG) procedures, and also significantly increases mortality rates in these patients. We believe the addition of MEDIHONEY to these expensive procedures will provide clinicians a cost-effective way to improve outcomes. Additionally, the recent increase in CABG procedures, due to efficacy concerns over less invasive forms of surgery and drug-eluting stent procedures, makes this an attractive and growing target market."

Quilty went on to say, "Use of the V.A.C. in post-surgical applications -- including DSWI -- has been steadily increasing. Overall, this product generates over $1 billion in revenues globally, and is the first true blockbuster in the field of wound care. Gaining acceptance as an adjunct to this therapy will add significantly to the global usage of MEDIHONEY."

The study was published in the proceedings of the 5th Annual Joint Meeting of the German, Austrian, and Swiss Societies for Cardiovascular and Thoracic Surgery as a special publication of the Journal of the Thoracic and Cardiovascular Surgeon. The investigators reported that there were no local or systemic adverse reactions to the treatment and that all patients progressed to complete wound healing. In the six patients who received application of MEDIHONEY every four days, the wounds were clean and sterile after a mean duration of treatment of 23 days. The two patients that received fewer applications of MEDIHONEY showed repeat positive wound cultures. No nosocomially acquired "superinfections" (including MRSA and VRE) were seen.

To read the abstract, please go to: (Information in this article concerns a use that has not been cleared by the US Food and Drug Administration.)

About deep sternal wound infections

Deep sternal wound infections occur in roughly 0.8% to 2% of patients undergoing median sternotomy and CABG. This rate increases to as high as 5.6% for diabetic patients, who make up between 17% and 20% of all patients undergoing CABG surgery. DSWI is associated with an average hospital stay increase of 16 days (average cost of over $25,000) and a higher mortality rate (19% versus 3.8% in patients without infection). Although the number of CABG procedures had been in decline since 2000 due to the advent of percutaneous coronary interventions (PCI) and drug-eluting stent (DES) procedures, recent questions into the safety and efficacy of these procedures has led to a 0.9% growth in CABG procedures. Approximately 800,000 to 1 million CABG procedures are performed globally each year. The worldwide CABG market is roughly $36 billion.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large scale randomized controlled trial on leg ulcers. For more information about Derma Sciences, Inc., visit its home page on the Internet at

Contact: Derma Sciences Inc Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO

(609) 514-4744 Brian Kennedy (media)

(212) 691-8087

SOURCE Derma Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
2. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
3. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
4. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
5. Cardiologists Tackle Next Frontier in Cardiovascular Disease
6. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
7. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
8. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
9. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
10. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
11. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
Breaking Medicine News(10 mins):